Literature DB >> 21576946

FcεRI-Toll-like receptor interaction in atopic dermatitis.

Natalija Novak, Thomas Bieber.   

Abstract

Exogenous factors such as allergens and microbial components play an important role as triggers of atopic dermatitis (AD). According to the current disease model, allergens as well as microbial antigens get into contact with surface receptors expressed by dendritic cells (DCs) in the skin of patients with AD. Allergen binding is most likely by the high-affinity receptor for IgE (FcεRI), which is highly expressed by epidermal DCs in AD. Beyond, pattern recognition receptors such as Toll-like receptors (TLRs) sense the environment for pathogen-associated molecular patterns. Combined stimulation of both receptor types by allergens and microbial antigens in the cellular micro-environment occurs frequently in AD. Modifications in the gene regions encoding those receptors as well as the pattern of DCs in the skin, the influence of the micro-environment together with the nature of incoming signals determine the type of immune response induced by FcεRI-and TLR-bearing DCs.
Copyright © 041_ S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576946     DOI: 10.1159/000323295

Source DB:  PubMed          Journal:  Curr Probl Dermatol        ISSN: 1421-5721


  2 in total

1.  Filaggrin mutations increase allergic airway disease in childhood and adolescence through interactions with eczema and aeroallergen sensitization.

Authors:  Adrian Chan; William Terry; Hongmei Zhang; Wilfried Karmaus; Susan Ewart; John W Holloway; Graham Roberts; Ramesh Kurukulaaratchy; Syed Hasan Arshad
Journal:  Clin Exp Allergy       Date:  2018-02       Impact factor: 5.018

2.  Impaired Toll-like receptor 2-mediated Th1 and Th17/22 cytokines secretion in human peripheral blood mononuclear cells from patients with atopic dermatitis.

Authors:  Yangyang Yu; Yarui Zhang; Jie Zhang; Xia Dou; Hong Yang; Yong Shao; Kepeng Wang; Bo Yu; Wei Zhang; Hang Yung Alaster Lau
Journal:  J Transl Med       Date:  2015-12-18       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.